Instinct Bio Nasdaq debut set after Relativity de-SPAC closes

The Instinct Bio Nasdaq debut gives retail investors a new longevity and regenerative-medicine name to track, with common shares set to trade as BIOT and warrants as BIOTW on July 24, 2026. The listing follows the completion of Instinct Bio Technical Company Holdings Inc.’s business combination with Relativity Acquisition Corp., a special purpose acquisition company, at a pro forma enterprise value of about $288 million, the companies announced.

A special purpose acquisition company, or SPAC, raises money first and then merges with an operating business. That process, often called a de-SPAC, can move a private company onto a public exchange without a traditional initial public offering.

For investors scanning new tickers, the setup is straightforward: BIOT is the common stock, while BIOTW represents warrants. Warrants are exchange-listed securities that typically give holders the right to buy shares under set terms, so they can trade differently from the common stock.

What is Instinct Bio?

Instinct Bio is a Tokyo-headquartered company focused on regenerative medicine, longevity, stem cell-derived products, wellness products and advanced skincare. Its operating footprint spans Tokyo, Las Vegas and New York, with commercial activity across Asia, according to the announcement.

The company describes itself as vertically integrated, meaning it combines research, manufacturing and commercialization inside one platform rather than outsourcing or splitting those functions across separate partners. In practical terms, that can matter because public-market investors are not just looking at a research story, but also at whether a company has products, customers and manufacturing capacity.

Instinct Bio’s pitch to the market is that it sits between life sciences and consumer health. That is a wide category, covering everything from regenerative health technologies to skincare products tied to stem cell research. The company said its strategy includes expanding stem cell and regenerative medicine research, scaling manufacturing, rolling out premium regenerative health and skincare products, pursuing partnerships and licensing, and growing internationally.

The broader sector claim is also part of the investment story. Citing research firm SNS Insider, the companies said the global longevity and wellness market is projected to rise from about $27.6 billion in 2025 to about $67.0 billion by 2035, driven by aging demographics, higher consumer healthcare spending and advances in stem cell science.

Tomoki Nagano, Instinct Bio’s chairman and chief executive, framed the Nasdaq listing as a way to gain visibility and a public-company platform for expanding stem cell technologies, manufacturing and product distribution. Tarek K. Tabsh, chief executive of Relativity Acquisition Corp., said the transaction came after a difficult period for the IPO market and credited investors, advisers and partners involved in the deal.

The new listing adds a publicly traded pure-play longevity and regenerative-medicine platform to the U.S. market, a sector that can carry both commercial promise and scientific risk. For retail investors, the key items to watch after the Instinct Bio regenerative medicine Nasdaq listing begins will be revenue mix, manufacturing progress, product expansion, and how the company supports its claims as a public issuer.